133 related articles for article (PubMed ID: 2432130)
1. The glycine-alanine repeating region is the major epitope of the Epstein-Barr nuclear antigen-1 (EBNA-1).
Rumpold H; Rhodes GH; Bloch PL; Carson DA; Vaughan JH
J Immunol; 1987 Jan; 138(2):593-9. PubMed ID: 2432130
[TBL] [Abstract][Full Text] [Related]
2. Human immune responses to synthetic peptides from the Epstein-Barr nuclear antigen.
Rhodes G; Carson DA; Valbracht J; Houghten R; Vaughan JH
J Immunol; 1985 Jan; 134(1):211-6. PubMed ID: 2981091
[TBL] [Abstract][Full Text] [Related]
3. Immune response to different sequences of the EBNA I molecule in Epstein-Barr virus-related disorders and in autoimmune diseases.
Marchini B; Dolcher MP; Sabbatini A; Klein G; Migliorini P
J Autoimmun; 1994 Apr; 7(2):179-91. PubMed ID: 7518683
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I.
Sabbatini A; Bombardieri S; Migliorini P
Eur J Immunol; 1993 May; 23(5):1146-52. PubMed ID: 8386666
[TBL] [Abstract][Full Text] [Related]
5. Altered immune response to glycine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus.
Petersen J; Rhodes G; Roudier J; Vaughan JH
Arthritis Rheum; 1990 Jul; 33(7):993-1000. PubMed ID: 2164400
[TBL] [Abstract][Full Text] [Related]
6. Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody.
Maunders MJ; Petti L; Rowe M
J Gen Virol; 1994 Apr; 75 ( Pt 4)():769-78. PubMed ID: 7512118
[TBL] [Abstract][Full Text] [Related]
7. The p542 gene encodes an autoantigen that cross-reacts with EBNA-1 of the Epstein Barr virus and which may be a heterogeneous nuclear ribonucleoprotein.
Rhodes GH; Valbracht JR; Nguyen MD; Vaughan JH
J Autoimmun; 1997 Oct; 10(5):447-54. PubMed ID: 9376072
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to synthetic peptides from Epstein-Barr nuclear antigen-1 in sera of patients with early rheumatoid arthritis and in preillness sera.
Kouri T; Petersen J; Rhodes G; Aho K; Palosuo T; Heliövaara M; Isomäki H; von Essen R; Vaughan JH
J Rheumatol; 1990 Nov; 17(11):1442-9. PubMed ID: 2177109
[TBL] [Abstract][Full Text] [Related]
9. Antibodies in rheumatoid arthritis react specifically with the glycine alanine repeat sequence of Epstein-Barr nuclear antigen-1.
Baboonian C; Halliday D; Venables PJ; Pawlowski T; Millman G; Maini RN
Rheumatol Int; 1989; 9(3-5):161-6. PubMed ID: 2481875
[TBL] [Abstract][Full Text] [Related]
10. A monoclonal antibody that recognizes Epstein-Barr virus nuclear antigen 2 (EBNA 2) amino acids 1-58 does not react with EBNA 2 in native form, consistent with the self-association of EBNA 2 through the amino-terminus.
Harada S; Obayashi M; Suzuki C; Kitamura R; Eda H; Kikuta H; Satoh H; Sugihara K; Yanagi K
Arch Virol; 2005 May; 150(5):1033-43. PubMed ID: 15662486
[TBL] [Abstract][Full Text] [Related]
11. Lack of reactivity of rheumatoid arthritis synovial membrane DNA with cloned Epstein Barr virus DNA probes.
Fox RI; Chilton T; Rhodes G; Vaughan JH
J Immunol; 1986 Jul; 137(2):498-501. PubMed ID: 3013992
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies in infectious mononucleosis have specificity for the glycine-alanine repeating region of the Epstein-Barr virus nuclear antigen.
Rhodes G; Rumpold H; Kurki P; Patrick KM; Carson DA; Vaughan JH
J Exp Med; 1987 Apr; 165(4):1026-40. PubMed ID: 2435830
[TBL] [Abstract][Full Text] [Related]
13. Cross reaction of antibodies to a glycine/alanine repeat sequence of Epstein-Barr virus nuclear antigen-1 with collagen, cytokeratin, and actin.
Baboonian C; Venables PJ; Williams DG; Williams RO; Maini RN
Ann Rheum Dis; 1991 Nov; 50(11):772-5. PubMed ID: 1722966
[TBL] [Abstract][Full Text] [Related]
14. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis.
Pratesi F; Tommasi C; Anzilotti C; Chimenti D; Migliorini P
Arthritis Rheum; 2006 Mar; 54(3):733-41. PubMed ID: 16508937
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a cellular protein that cross-reacts with the Epstein-Barr virus nuclear antigen.
Luka J; Kreofsky T; Pearson GR; Hennessy K; Kieff E
J Virol; 1984 Dec; 52(3):833-8. PubMed ID: 6208381
[TBL] [Abstract][Full Text] [Related]
16. Carboxyl-terminal domain of the Epstein-Barr virus nuclear antigen is highly immunogenic in man.
Milman G; Scott AL; Cho MS; Hartman SC; Ades DK; Hayward GS; Ki PF; August JT; Hayward SD
Proc Natl Acad Sci U S A; 1985 Sep; 82(18):6300-4. PubMed ID: 2412231
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen.
Dillner J; Sternås L; Kallin B; Alexander H; Ehlin-Henriksson B; Jörnvall H; Klein G; Lerner R
Proc Natl Acad Sci U S A; 1984 Aug; 81(15):4652-6. PubMed ID: 6205400
[TBL] [Abstract][Full Text] [Related]
18. [Epstein-Barr virus antibodies: review of results from repeated examinations in 208 hemodialyzed patients].
Korcáková L
Vnitr Lek; 1995 Jun; 41(6):377-9. PubMed ID: 7676656
[TBL] [Abstract][Full Text] [Related]
19. A systematic study of Epstein-Barr virus serologic assays following acute infection.
Rea TD; Ashley RL; Russo JE; Buchwald DS
Am J Clin Pathol; 2002 Jan; 117(1):156-61. PubMed ID: 11789721
[TBL] [Abstract][Full Text] [Related]
20. Serological follow-up study on the antibody levels to Epstein-Barr virus-determined nuclear antigen (EBNA) patients with nasopharyngeal carcinoma (NPC) after radiation therapy.
Shimakage M; Ikegami N; Chatani M; Yoshino K; Sato T
Biken J; 1987 Jun; 30(2):45-51. PubMed ID: 2830879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
